Novo Nordisk

Novo Nordisk's Wegovy pill has become the fastest-growing GLP-1 oral treatment, reaching over 5 million prescriptions since January launch with accelerating adoption (1 million patients added in first 12 weeks, latest 1 million in just one month). Q1 sales nearly doubled Wall Street expectations. CEO highlighted unexpected patient preference for pill over injection form. Strong direct-to-consumer channel driving growth, though manufacturing capacity remains a concern versus rival Eli Lilly.